Reuters logo
BRIEF-Galena biopharma reports positive outcome from the data safety monitoring board on the two Neuvax trials
February 6, 2017 / 12:22 PM / 10 months ago

BRIEF-Galena biopharma reports positive outcome from the data safety monitoring board on the two Neuvax trials

Feb 6 (Reuters) - Galena Biopharma Inc

* Galena Biopharma reports positive outcome from the data safety monitoring board on the two neuvax (nelipepimut-s) clinical trials in combination with trastuzumab

* Interim efficacy analysis for low-to-intermediate (her2 1+/2+) trial now expected by end of 2017

* Says interim efficacy analysis for low-to-intermediate (her2 1+/2+) trial now expected by end of 2017

* Both combination trials are deemed not futile and data safety monitoring board recommends that both trials continue

* DSMB expects to perform interim efficacy analysis near end of 2017

* Says data safety monitoring board reported that there are no safety concerns with either trial and neither was found to be futile

* Phase 2 trial showed agent is well tolerated with no increased cardiotoxicity associated with giving Neuvax with Trastuzumab Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below